Advertisement

Topics

Orphan drug designation received for acute myeloid leukaemia treatment

08:03 EDT 23 Aug 2017 | EPM Magazine

The US Food and Drug Administration (FDA) has granted orphan drug designation to SY-1425, which is an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist for the treatment of acute myeloid leukaemia (AML) from Syros

Original Article: Orphan drug designation received for acute myeloid leukaemia treatment

NEXT ARTICLE

More From BioPortfolio on "Orphan drug designation received for acute myeloid leukaemia treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...